secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longboard Pharmaceuticals, Inc. (—)
CIK:        0001832168
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-052111
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longboard Q1 2024: $321M cash; bexicaserin Phase 3 on track for YE 2024
-----------------------------------------------------------------------

- Cash, cash equivalents and investments of $321.0M as of March 31, 2024; cash runway into 2027.
- Net proceeds of $226.5M from Jan 2024 follow-on offering (11.5M shares at $21.00) and $59.9M from private placement (2.85M non-voting shares at $21.00).
- R&D expenses $13.2M (+54% YoY), primarily due to bexicaserin and LP659 trial costs.
- Positive topline PACIFIC Study data for bexicaserin presented at AAN April 2024; global Phase 3 to start by YE 2024.
- LP659 Phase 1 SAD topline data expected Q2 2024; PACIFIC open-label extension data in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832168/000095017024052111/0000950170-24-052111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832168/000095017024052111/lbph-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-052111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer